Precision NanoSystems launches NanoAssemblr Scale-Up system to support production of novel medicines

Precision NanoSystems has launched the NanoAssemblr™ Scale-Up system to support the clinical development of nanomedicines. This latest addition to the NanoAssemblr range is designed for the manufacture of clinical trial material in GMP environments, and will support the production of novel medicines, including siRNA, mRNA and CRISPR/Cas9 therapeutics.

The NanoAssemblr range supports nanoparticle research from proof-of-concept to scale-up

The NanoAssemblr Scale-Up system features the same proprietary microfluidic mixing technology as the company’s preclinical instruments – the NanoAssemblr Benchtop™ and Blaze™ – providing seamless scale-up following formulation development. Its compact, modular design uses a fully disposable fluid path with multiple microfluidic mixers connected in parallel to produce a single large volume batch in less time, and is ideally suited to manufacturing batch volumes sufficient for clinical trials.

“The NanoAssemblr Scale-Up system is designed to provide customers with a customizable, modular platform for the cGMP manufacture of high quality nanomedicines,” commented Ray Lockard, Vice President of Pharmaceutical Operations at Precision NanoSystems. “By using the same underlying technology as the rest of the NanoAssemblr instrument portfolio, this will allow researchers to accelerate product development from discovery to the clinic and, ultimately, help to realize the potential for novel therapeutic modalities, such as genome editing and mRNA-mediated protein expression.”

The NanoAssemblr Scale-Up system can be viewed at Precision NanoSystems’ facilities in Vancouver, BC, and South San Francisco, CA.